Financial News · Live Terminal

Page 34 of 193

Jacobs Solutions Fiscal Q2 Earnings, Revenue Rise

Jacobs Solutions (J) reported fiscal Q2 adjusted earnings late Tuesday of $1.75 per diluted share, up from $1.43 a year earlier.Analysts polled by FactSet expected $1.63.Revenue in the three months ended March 27 rose to $3.69 billion from $2.91 billion a year ago.Jacobs boosted fiscal 2026 adjusted EPS guidance to the range of $7.10 to $7.35 from the prior forecast of $6.95 to $7.30.Analysts polled by FactSet expect $7.12.Jacobs shares fell 4.8% in after-hours trading.

Australia4d ago

Tempus AI Q1 Non-GAAP Loss Narrows, Revenue Rises; Revises 2026 Revenue Guidance

Tempus AI (TEM) reported a Q1 non-GAAP net loss late Tuesday of $0.13 per basic share, narrowing from a loss of $0.24 a year earlier.Analysts polled by FactSet expected a loss of $0.20.Revenue for the quarter ended March 31 was $348.1 million, up from $255.7 million a year earlier.Analysts surveyed by FactSet expected $345.4 million.The company raised its full-year 2026 revenue guidance to $1.59 billion to $1.60 billion from the prior forecast of $1.59 billion. Analysts expect $1.59 billion.Shares of Tempus AI were down more than 5% in after-hours activity.

$TEM

Australia4d ago

Astera Labs Q1 Non-GAAP Earnings, Revenue Rise

Astera Labs (ALAB) reported Q1 non-GAAP earnings late Tuesday of $0.61 per diluted share, up from $0.33 a year earlier.Analysts polled by FactSet expected $0.54.Revenue in the three months ended March 31 rose to $308.4 million from $159.4 million a year earlier.Analysts polled by FactSet expected $292.2 million.The company expects Q2 non-GAAP diluted EPS of $0.68 to $0.70 on revenue of $355 million to $365 million. Analysts expect EPS of $0.55 on revenue of $310.1 million.Astera shares rose 2.5% in after-hours trading.

$ALAB

Australia4d ago

Earnings Flash (MSTR) Strategy Posts Q1 Loss -$38.25

Price: $187.30, Change: $+3.50, Percent Change: +1.90%

$MSTR

Australia4d ago

Earnings Flash (MSTR) Strategy Posts Q1 Revenue $124.3M, vs. FactSet Est of $120.8M

Price: $187.10, Change: $+3.30, Percent Change: +1.80%

$MSTR

Australia4d ago

Top Cryptocurrencies Rise; Bitcoin Tops $81,000

Major digital assets rose Tuesday with Bitcoin (BTC-USD) topping $81,000.The CoinDesk Market Index, which tracks dozens of digital assets including Bitcoin, rose almost 1.3% in the past 24 hours. The Nasdaq 100 was up 1.4%, the S&P 500 rose 0.9%, and the Dow Jones Industrial Average added 0.9%.Bitcoin rose 2% to $81,657, according to CoinMarketCap data. The most popular cryptocurrency's 24-hour trading volume decreased 34% to $37.2 billion.Ethereum (ETH-USD), the second-largest digital asset by market value, added 0.8% to $2,375.XRP (XRP-USD) gained 1%, BNB (BNB-USD) rose 1.1%, and Solana (SOL-USD) added 2.4%. Dogecoin (DOGE-USD) climbed 2.9%, while Cardano (ADA-USD) was up 2.9%.The US 10-year Treasury yield stood at 4.413% at 3 p.m. ET Tuesday, down from 4.447% Monday, while the five-year yield fell to 4.069% from 4.093%.The total market value of the cryptocurrency industry rose 1.7% in the past 24 hours to $2.69 trillion, with trading volume gaining 1.8% to $164.38 billion.Price: $81530.92, Change: $+1706.70, Percent Change: +2.14%

$ADA-USD$BNB-USD$BTC-USD$DOGE-USD$ETH-USD$SOL-USD$XRP-USD

Australia4d ago

Brunswick Keeps Quarterly Dividend at $0.44 per Share, Payable June 15 to Holders of Record May 18

Price: $78.25, Change: $+3.79, Percent Change: +5.09%

$BC

Australia4d ago

Vertex Pharmaceuticals Confident in Emerging Renal Franchise, Oppenheimer Says

Vertex Pharmaceuticals' (VRTX) management remains confident in its emerging renal franchise, suggesting it could rival or even exceed its cystic fibrosis franchise eventually, Oppenheimer said in a Tuesday note.The strong uptake of Alyftrek is encouraging, and Oppenheimer expects continued growth in US and international markets, driven by adoption among treatment-naive patients, those who previously discontinued cystic fibrosis therapy, and patients who switched to Alyftrek, according to the note.Uptake of Alyftrek among younger patients and more access in Europe should support long-term growth, according to the note. For Journavx, management remains confident in tripling total scripts in 2026, the brokerage said.Management remains confident in Pove's profile, and the recent submission completion for Pove suggests a potential FDA decision by year-end, according to the note.Oppenheimer said Inaxaplin represents the next key catalyst, with the phase 2 AMPLIFIED study readout now expected in H2, compared with the prior mid-2026 guidance.Oppenheimer maintained an outperform rating on Vertex Pharmaceuticals with a price target of $600.Price: $423.92, Change: $-5.93, Percent Change: -1.38%

$VRTX

Australia4d ago

Pony AI Shares Fall After President Capital Downgrade

Pony AI (PONY) shares were down 1.4% in Tuesday afternoon trading after President Capital downgraded the stock to neutral from buy.Intraday trading volume stood at about 1.3 million shares against a daily average of roughly 4.3 million.Price: $10.25, Change: $-0.15, Percent Change: -1.44%

$PONY

Australia4d ago

Market Chatter: Citigroup Plans to Introduce New Medium-Term Profitability Targets at Upcoming Investor Day

Citigroup (C) plans to introduce new medium-term profitability targets at its upcoming investor day on Thursday, Reuters reported Tuesday, citing an interview with chief executive officer Jane Fraser.The bank will also highlight improvements in expenses and revenue from its multi-year reorganization, the news outlet said, adding that Citigroup is also betting on artificial intelligence to aid growth in its wealth business.Fraser told that the company will be laying out new return targets and the growth path for each of the businesses, and that the bank plans to raise the bar beyond its 2026 goals, according to the report.Citigroup did not immediately respond to' request for comment.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.) withPrice: $127.94, Change: $+2.31, Percent Change: +1.84%

Australia4d ago

Cogent Communications Shares Rise After JPMorgan Upgrade

Cogent Communications (CCOI) shares were up over 11% in Tuesday trading after JPMorgan upgraded the stock to overweight from neutral while lowering its price target to $22 from $23.Separately, UBS also cut its price target to $17 from $21 while maintaining its neutral rating.Trading volume stood at more than 2.5 million shares, compared with a daily average of roughly 1.3 million.Price: $18.29, Change: $+1.92, Percent Change: +11.70%

$CCOI

Australia4d ago

Warby Parker Faces 'Challenging' Q1 on Weather, Consumer Pressure, UBS Says

Warby Parker (WRBY) is expected to post a "challenging" Q1, UBS Securities said, adding that results will likely be impacted by "severe winter weather" and increasing pressure on the consumer from rising gasoline prices.The brokerage said in a Monday research note that the retailer's "core cash paying customer may have faced added stress," pointing to higher fuel costs and broader macro uncertainty, with pressure especially affecting younger and lower-income consumers.UBS noted that Q1 growth would represent the company's slowest pace on record, highlighting the extent of a slowdown. It added that recent commentary suggests Warby is "braced for more downside vs upside risk from the consumer."The investment firm also flagged that margins may face pressure from tariffs, cost deleverage in COGS and SG&A, and other input costs, though some of that could be offset by price increases, mix shift toward higher-margin products and cost mitigation efforts.However, the firm said the "smart glasses opportunity" remains the key near-term driver for the stock and highlighted it as a potential catalyst.UBS has a neutral rating on the company's stock, with a $25 price target.Price: $21.65, Change: $-0.34, Percent Change: -1.55%

$WRBY

Australia4d ago

Assurant Q1 Adjusted Earnings, Revenue Rise

Assurant (AIZ) reported Q1 adjusted earnings Tuesday of $5.95 per diluted share, up from $3.39 a year earlier.Analysts polled by FactSet expected $5.29.Revenue for the three months ended March 31 was $3.42 billion, up from $3.07 billion a year earlier.Analysts surveyed by FactSet expected $3.29 billion.For the full-year 2026, the company now expects adjusted EPS to increase in the low single digits.Price: $237.90, Change: $+8.78, Percent Change: +3.83%

$AIZ

Australia4d ago

Piper Sandler Cuts Shopify Price Target to $150 From $165, Overweight Rating Kept

Shopify (SHOP) has an average rating of overweight and mean price target of $160.15, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $105.83, Change: $-21.72, Percent Change: -17.03%

$SHOP

Australia4d ago

Piper Sandler Cuts Price Target on Henry Schein to $91 From $99

Henry Schein (HSIC) has an average rating of overweight and mean price target of $90.21, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $74.05, Change: $+2.03, Percent Change: +2.82%

$HSIC

Australia4d ago

HSBC Raises Caterpillar Price Target to $1,100 From $850

Caterpillar (CAT) has an average rating of overweight and mean price target of $893.22, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $899.58, Change: $+24.80, Percent Change: +2.83%

$CAT

Australia4d ago

Piper Sandler Lifts Price Target on KKR to $125 From $117

KKR (KKR) has an average rating of buy and mean price target of $124.61, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $101.18, Change: $-2.15, Percent Change: -2.08%

$KKR

Australia4d ago

Deutsche Bank Cuts Price Target on Northrop Grumman to $691 From $778, Maintains Buy Rating

Northrop Grumman (NOC) has an average rating of overweight and mean price target of $728.45, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $554.51, Change: $-12.50, Percent Change: -2.20%

$NOC

Australia4d ago

Roblox Shares Fall After Piper Sandler Downgrade

Roblox (RBLX) shares fell 6.8% on Tuesday after Piper Sandler downgraded the stock to neutral from overweight and cut its price target to $50 per share from $100.Trading volume stood at over 9.4 million shares compared with a daily average of nearly 10.9 million.Price: $44.32, Change: $-3.25, Percent Change: -6.83%

$RBLX

Australia4d ago

Update: IPG Photonics Shares Drop After Q1 Adjusted Earnings Fall

(Updates with recent stock movement in headline and first paragraph.)IPG Photonics (IPGP) shares dropped about 30% in afternoon trading on Tuesday after the company posted lower Q1 adjusted earnings.The company reported Q1 adjusted earnings Tuesday of $0.29 per diluted share, down from $0.31 a year earlier.An analyst polled by FactSet expected $0.31.Revenue for the quarter ended March 31 was $265.5 million, compared with $227.8 million a year earlier.An analyst polled by FactSet expected $265.5 million.The company expects Q2 adjusted EPS of $0.25 to $0.55 and $260 million to $290 million in revenue. Analysts polled by FactSet expect $0.44 in adjusted EPS on revenue of $275.7 million.Separately, IPG Photonics said it agreed on a global settlement with TRUMPF Laser- und Systemtechnik to resolve and close their patent dispute. No other details were disclosed.Price: $86.18, Change: $-36.16, Percent Change: -29.56%

$IPGP

Showing 661-680 of 3847